157 related articles for article (PubMed ID: 30310249)
41. Benchmarking docking and scoring protocol for the identification of potential acetylcholinesterase inhibitors.
Zaheer-ul-Haq ; Halim SA; Uddin R; Madura JD
J Mol Graph Model; 2010 Jun; 28(8):870-82. PubMed ID: 20447848
[TBL] [Abstract][Full Text] [Related]
42. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.
Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA
CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169
[TBL] [Abstract][Full Text] [Related]
43. Identifying Possible AChE Inhibitors from Drug-like Molecules via Machine Learning and Experimental Studies.
Nguyen TH; Tran PT; Pham NQA; Hoang VH; Hiep DM; Ngo ST
ACS Omega; 2022 Jun; 7(24):20673-20682. PubMed ID: 35755364
[TBL] [Abstract][Full Text] [Related]
44. Multitargeted Molecular Docking and Dynamic Simulation Studies of Bioactive Compounds from
Mirza FJ; Zahid S; Amber S; Sumera ; Jabeen H; Asim N; Ali Shah SA
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364071
[TBL] [Abstract][Full Text] [Related]
45. Alignment-independent 3D-QSAR and molecular docking studies of tacrine-4-oxo-4H-Chromene hybrids as anti-Alzheimer's agents.
Manouchehrizadeh E; Mostoufi A; Tahanpesar E; Fereidoonnezhad M
Comput Biol Chem; 2019 Jun; 80():463-471. PubMed ID: 31170562
[TBL] [Abstract][Full Text] [Related]
46. A Cobalt-Containing Compound as a Stronger Inhibitor than Galantamine to Inhibit Acetylcholinesterase Activity: A New Drug Candidate for Alzheimer's Disease Treatment.
Kalari M; Abbasi Z; Shasaltaneh MD; Khaleghian A; Moosavi-Nejad Z
J Alzheimers Dis; 2022; 87(4):1503-1516. PubMed ID: 35527546
[TBL] [Abstract][Full Text] [Related]
47. In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease.
Hu XM; Dong W; Cui ZW; Gao CZ; Yu ZJ; Yuan Q; Min ZL
J Mol Model; 2018 Jun; 24(7):151. PubMed ID: 29869722
[TBL] [Abstract][Full Text] [Related]
48. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
Gurung AB; Aguan K; Mitra S; Bhattacharjee A
J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
[TBL] [Abstract][Full Text] [Related]
49. Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons.
Fayuk D; Yakel JL
Mol Pharmacol; 2004 Sep; 66(3):658-66. PubMed ID: 15322258
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and biological activity of novel tacrine-isatin Schiff base hybrid derivatives.
Riazimontazer E; Sadeghpour H; Nadri H; Sakhteman A; Tüylü Küçükkılınç T; Miri R; Edraki N
Bioorg Chem; 2019 Aug; 89():103006. PubMed ID: 31158577
[TBL] [Abstract][Full Text] [Related]
51. Identification of Natural Compounds of the Apple as Inhibitors against Cholinesterase for the Treatment of Alzheimer's Disease: An In Silico Molecular Docking Simulation and ADMET Study.
Jamal QMS; Khan MI; Alharbi AH; Ahmad V; Yadav BS
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049419
[TBL] [Abstract][Full Text] [Related]
52. In silico screening of glycogen synthase kinase-3β targeted ligands against acetylcholinesterase and its probable relevance to Alzheimer's disease.
Jabir NR; Shakil S; Tabrez S; Khan MS; Rehman MT; Ahmed BA
J Biomol Struct Dyn; 2021 Sep; 39(14):5083-5092. PubMed ID: 32588759
[TBL] [Abstract][Full Text] [Related]
53. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
Musiał A; Bajda M; Malawska B
Curr Med Chem; 2007; 14(25):2654-79. PubMed ID: 17979717
[TBL] [Abstract][Full Text] [Related]
54. Synthesis, molecular docking and molecular dynamics studies of novel tacrine-carbamate derivatives as potent cholinesterase inhibitors.
Ozten O; Zengin Kurt B; Sonmez F; Dogan B; Durdagi S
Bioorg Chem; 2021 Oct; 115():105225. PubMed ID: 34364052
[TBL] [Abstract][Full Text] [Related]
55. Proposing novel natural compounds against Alzheimer's disease targeting acetylcholinesterase.
Girgin M; Isik S; Kantarci-Carsibasi N
PLoS One; 2023; 18(4):e0284994. PubMed ID: 37104478
[TBL] [Abstract][Full Text] [Related]
56. Rapid screening for acetylcholinesterase inhibitors in Selaginella doederleinii Hieron by using functionalized magnetic Fe
Zhang F; Li S; Liu C; Fang K; Jiang Y; Zhang J; Lan J; Zhu L; Pang H; Wang G
Talanta; 2022 Jun; 243():123284. PubMed ID: 35255433
[TBL] [Abstract][Full Text] [Related]
57. Hydroxybenzoic Acids as Acetylcholinesterase Inhibitors: Calorimetric and Docking Simulation Studies.
Budryn G; Majak I; Grzelczyk J; Szwajgier D; Rodríguez-Martínez A; Pérez-Sánchez H
Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745206
[TBL] [Abstract][Full Text] [Related]
58. Revealing the mechanistic pathway of cholinergic inhibition of Alzheimer's disease by donepezil: a metadynamics simulation study.
Ghosh S; Jana K; Ganguly B
Phys Chem Chem Phys; 2019 Jul; 21(25):13578-13589. PubMed ID: 31173012
[TBL] [Abstract][Full Text] [Related]
59. Revealing the cholinergic inhibition mechanism of Alzheimer's by galantamine: a metadynamics simulation study.
Ghosh S; Jana K; Wakchaure PD; Ganguly B
J Biomol Struct Dyn; 2022 Jul; 40(11):5100-5111. PubMed ID: 33382027
[TBL] [Abstract][Full Text] [Related]
60. Synthesis, characterization, evaluation of metabolic enzyme inhibitors and in silico studies of thymol based 2-amino thiol and sulfonic acid compounds.
Bora RE; Genc Bilgicli H; Üç EM; Alagöz MA; Zengin M; Gulcin İ
Chem Biol Interact; 2022 Oct; 366():110134. PubMed ID: 36057360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
